2005
DOI: 10.1128/jvi.79.17.10864-10874.2005
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: We report here the generation of transgenic chickens using a retroviral vector for the production of recombinant proteins. It was found that the transgene expression was suppressed when a Moloney murine leukemia virus-based retroviral vector was injected into chicken embryos at the blastodermal stage. When a concentrated viral solution was injected into the heart of developing embryos after 50 to 60 h of incubation, transgene expression was observed throughout the embryo, including the gonads. For practical pr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

2
110
1
4

Year Published

2007
2007
2023
2023

Publication Types

Select...
5
2

Relationship

2
5

Authors

Journals

citations
Cited by 119 publications
(117 citation statements)
references
References 46 publications
2
110
1
4
Order By: Relevance
“…The basic strategy used has been to target expression of a therapeutic protein to a protein secretory tissue, often the mammary gland, using the regulatory sequences of one of the native proteins synthesized in that tissue. The production of therapeutic proteins has now been demonstrated in transgenic mammals, including sheep, goats, cattle, rabbits (1,2), and chickens (3)(4)(5). The use of transgenic chickens as bioreactors to synthesize therapeutic proteins, as a component of egg yolk or white, may have several advantages over mammalian expression systems, including a shorter timescale for setup and ease of scaleup to a transgenic flock, lower costs associated with husbandry, the potential to produce proteins that are toxic to mammalian cells, beneficial glycosylation profile, and reduced immunogenicity of the purified product (reviewed in ref.…”
mentioning
confidence: 99%
“…The basic strategy used has been to target expression of a therapeutic protein to a protein secretory tissue, often the mammary gland, using the regulatory sequences of one of the native proteins synthesized in that tissue. The production of therapeutic proteins has now been demonstrated in transgenic mammals, including sheep, goats, cattle, rabbits (1,2), and chickens (3)(4)(5). The use of transgenic chickens as bioreactors to synthesize therapeutic proteins, as a component of egg yolk or white, may have several advantages over mammalian expression systems, including a shorter timescale for setup and ease of scaleup to a transgenic flock, lower costs associated with husbandry, the potential to produce proteins that are toxic to mammalian cells, beneficial glycosylation profile, and reduced immunogenicity of the purified product (reviewed in ref.…”
mentioning
confidence: 99%
“…The establishment and basic characteristics of genetically manipulated chickens that expressed scFv/Fc were described previously (Kamihira et al 2005). These were generated by the injection of a concentrated retroviral vector into the heart of 2.5-day embryos.…”
Section: Analysis Of Sialylation In Scfv/fc From the Yolkmentioning
confidence: 99%
“…These were generated by the injection of a concentrated retroviral vector into the heart of 2.5-day embryos. scFv/Fc was purified from the yolk of one of the highest producers in the first generation (G 0 ; #407, accumulating scFv/Fc at a concentration of 0.25-0.5 mg/mL in the yolk) as described previously (Kamihira et al 2005). In brief, rProtein A Sepharose TM Fast Flow (GE Healthcare, Waukesha, WI, USA) was added to yolk that had been diluted 5 times with phosphate-buffered saline (PBS) and stirred overnight.…”
Section: Analysis Of Sialylation In Scfv/fc From the Yolkmentioning
confidence: 99%
See 2 more Smart Citations